PMDA posts MHLW notice instructing revisions to drug package insert precautions (Aug 7, 2026)
使用上の注意の改訂指示通知（医薬品）2026年08月7日付（厚生労働省より発出）を掲載しました
Published: 2026-08-12 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · First detected by this dashboard: 2026-08-13
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
The Pharmaceuticals and Medical Devices Agency (PMDA) posted a notice on its safety information pages, published 2026-08-12. The notice concerns an instruction to revise the 'precautions for use' (package insert precautions) of pharmaceutical products, issued by the Ministry of Health, Labour and Welfare and dated August 7, 2026. The provided metadata does not identify which drugs or which precautions are affected.
Business Impact
Marketing authorization holders and others who handle the affected pharmaceutical products may need to check whether the revised precautions apply to their products and whether labeling or information materials could be affected. The scope cannot be determined from the available metadata.
Recommended Action
Review the official PMDA page and the underlying Japanese-language MHLW notice to confirm the affected products, the specific revisions, and any applicable timelines.